Legal Settlements and Loss Contingencies	6 Months Ended
Jun. 30, 2020
Legal Settlements and Loss Contingencies	NOTE 9 – Legal settlements and loss contingencies: In the second quarter of 2020, Teva recorded an expense of $ 13 million in legal settlements and loss contingencies, compared to $ 646 million in the second quarter of 2019. The expense in the second quarter of 2020 was mainly due to the increase of a reserve for certain legal expenses and settlement contributions related to products liability claims in the United States, partially offset by proceeds received following a settlement of the FCPA derivative proceedings in Israel. The expense in the second quarter of 2019 was mainly related to the $ 85 million settlement paid in the opioid litigation brought by the Oklahoma Attorney General and an estimated provision made for certain other opioid cases. In the first six months of 2020, Teva recorded an income of $12 million in legal settlements and loss contingencies, compared to expense of $703 million in the first six months of 2019. The income in the first six months of 2020 was mainly due to proceeds received following a settlement of the FCPA derivative proceedings in Israel and settlement of a n action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics), partially offset by the increase of a reserve for certain legal expenses and settlement contributions related to products liability claims in the United States. The expense in the first six months of 2019 was mainly related to the $85 million settlement paid in the opioid litigation brought by the Oklahoma Attorney General and an estimated provision made for certain other opioid cases. As of June 30, 2020 and December 31, 2019, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses was $1,588 million and $1,580 million, respectively.

Legal Settlements and Loss Contingencies

6 Months Ended

Jun. 30, 2020

Legal Settlements and Loss Contingencies

NOTE 9 – Legal settlements and loss contingencies:

In the second quarter of 2020, Teva recorded an expense

of $

million

in legal settlements and loss contingencies, compared to

646

million in the second quarter of 2019. The expense in the second quarter of 2020 was mainly due to the increase of a reserve for certain legal expenses and settlement contributions related to products liability claims in the United States, partially offset by proceeds received following a settlement of the FCPA derivative proceedings in Israel. The expense in the second quarter of 2019 was mainly related to

the $

million

settlement paid in the opioid litigation brought by the Oklahoma Attorney General and an estimated provision made for certain other opioid cases.

In the first six months of 2020, Teva recorded an income of $12 million in legal settlements and loss contingencies, compared to expense of $703 million

in the first six months of 2019. The income in the first six months of 2020 was mainly due to proceeds received following a settlement of the FCPA derivative proceedings in Israel and settlement of a

action brought against the sellers of Auden McKenzie (an acquisition made by Actavis Generics), partially offset by the increase of a reserve for

certain

legal expenses and settlement contributions related to products liability claims in the United States. The expense in the first six months of 2019 was mainly related to the $85 million settlement paid in the opioid litigation brought by the Oklahoma Attorney General and an estimated provision made for certain other opioid cases.

As of June 30, 2020 and December 31, 2019, Teva’s provision for legal settlements and loss contingencies recorded under accrued expenses was $1,588 million and $1,580 million, respectively.